sertraline has been researched along with Depressive Disorder, Treatment-Resistant in 12 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 12 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Broadhouse, K; Gordon, E; Grieve, SM; Koslow, S; Maller, JJ; Rush, AJ | 1 |
| Hasegawa, S; Hida, H; Miyake, Y; Mouri, A; Nabeshima, T; Noda, Y; Ozaki, N; Yamada, K; Yoshimi, A | 1 |
| Bellomo, A; D'Urso, F; Daniele, A; Dibello, V; Giannelli, G; Greco, A; La Montagna, M; Logroscino, G; Lozupone, M; Panza, F; Piccininni, C; Quaranta, N; Sardone, R; Seripa, D; Solfrizzi, V | 1 |
| Bajbouj, M; Cooper, K; Daly, EJ; Drevets, WC; Hough, D; Lane, R; Lim, P; Manji, H; Mazzucco, C; Molero, P; Popova, V; Shelton, RC; Singh, JB; Thase, ME; Trivedi, M; Vieta, E | 1 |
| Ameele, HVD; Blier, P; Daly, EJ; Drevets, WC; Fava, M; Fedgchin, M; Gaillard, R; Hough, D; Lane, R; Liebowitz, M; Lim, P; Manji, H; Melkote, R; Preskorn, S; Ravindran, A; Singh, JB; Trivedi, M; Vitagliano, D | 1 |
| Furuse, K; Hashimoto, E; Ishii, T; Kigawa, Y; Saito, T; Shirasaka, T; Tsujino, H; Ukai, W | 1 |
| Demyttenaere, K; Dunbar, G; Eriksson, H; Hosford, D; Möller, HJ; Olausson, B; Szamosi, J; Tummala, R; Wilson, E | 1 |
| Gordon, E; Grieve, SM; Korgaonkar, MS; Rush, AJ; Williams, LM | 1 |
| Schwartz, TL | 1 |
| Dusetzina, SB; Ellis, AR; Farley, JF; Gaynes, BN; Hansen, RA; Miller, WC; Stürmer, T | 1 |
| Boku, S; Fujisawa, D; Honda, M; Inoue, T; Ishikane, T; Ito, K; Kawamura, K; Koyama, T; Matsubara, R; Ono, Y; Sasaki, K; Shinohara, K; Suzuki, T; Tsuchiya, K | 1 |
| Hori, H; Ikenouchi-Sugita, A; Iwata, N; Katsuki, A; Kishi, T; Nakamura, J; Umene-Nakano, W; Yoshimura, R | 1 |
1 review(s) available for sertraline and Depressive Disorder, Treatment-Resistant
| Article | Year |
|---|---|
Pharmacotherapy for the treatment of depression in patients with alzheimer's disease: a treatment-resistant depressive disorder.
Topics: Alzheimer Disease; Antipsychotic Agents; Calcium Channel Blockers; Clinical Trials as Topic; Depressive Disorder, Treatment-Resistant; Humans; Nimodipine; Piperazines; Selective Serotonin Reuptake Inhibitors; Sertraline; Sulfides; Vortioxetine | 2018 |
8 trial(s) available for sertraline and Depressive Disorder, Treatment-Resistant
| Article | Year |
|---|---|
Increased hippocampal tail volume predicts depression status and remission to anti-depressant medications in major depression.
Topics: Adult; Age Factors; Antidepressive Agents; Citalopram; Cohort Studies; Delayed-Action Preparations; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Female; Hippocampus; Humans; Image Interpretation, Computer-Assisted; Magnetic Resonance Imaging; Male; Organ Size; Pattern Recognition, Automated; Prognosis; Psychiatric Status Rating Scales; Remission Induction; Sertraline; Venlafaxine Hydrochloride | 2018 |
Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Combined With a Newly Initiated Oral Antidepressant in Treatment-Resistant Depression: A Randomized Double-Blind Active-Controlled Study.
Topics: Administration, Intranasal; Administration, Oral; Adult; Antidepressive Agents; Citalopram; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Double-Blind Method; Drug Therapy, Combination; Duloxetine Hydrochloride; Female; Humans; Ketamine; Male; Middle Aged; Sertraline; Treatment Outcome; Venlafaxine Hydrochloride | 2019 |
Efficacy and Safety of Fixed-Dose Esketamine Nasal Spray Combined With a New Oral Antidepressant in Treatment-Resistant Depression: Results of a Randomized, Double-Blind, Active-Controlled Study (TRANSFORM-1).
Topics: Administration, Intranasal; Administration, Oral; Adolescent; Adult; Antidepressive Agents; Citalopram; Delayed-Action Preparations; Depressive Disorder, Treatment-Resistant; Double-Blind Method; Drug Therapy, Combination; Duloxetine Hydrochloride; Female; Humans; Ketamine; Male; Middle Aged; Sertraline; Treatment Outcome; Venlafaxine Hydrochloride; Young Adult | 2019 |
Two Phase III randomised double-blind studies of fixed-dose TC-5214 (dexmecamylamine) adjunct to ongoing antidepressant therapy in patients with major depressive disorder and an inadequate response to prior antidepressant therapy.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Citalopram; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Logistic Models; Male; Mecamylamine; Middle Aged; Psychiatric Status Rating Scales; Sertraline; Treatment Outcome; Young Adult | 2015 |
Prediction of nonremission to antidepressant therapy using diffusion tensor imaging.
Topics: Adult; Antidepressive Agents; Brain; Citalopram; Delayed-Action Preparations; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Diffusion Magnetic Resonance Imaging; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Male; Middle Aged; Nerve Net; Predictive Value of Tests; Psychiatric Status Rating Scales; Sertraline; Venlafaxine Hydrochloride; White Matter; Young Adult | 2016 |
Treating depression after initial treatment failure: directly comparing switch and augmenting strategies in STAR*D.
Topics: Adolescent; Adult; Aged; Antidepressive Agents, Second-Generation; Bupropion; Buspirone; Citalopram; Cyclohexanols; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Substitution; Drug Therapy, Combination; Female; Humans; Likelihood Functions; Male; Middle Aged; Personality Inventory; Psychometrics; Quality of Life; Sertraline; United States; Venlafaxine Hydrochloride; Young Adult | 2012 |
Sertraline treatment of patients with major depressive disorder who failed initial treatment with paroxetine or fluvoxamine.
Topics: Adult; Aged; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Drug Administration Schedule; Female; Fluvoxamine; Humans; Male; Middle Aged; Paroxetine; Sertraline; Severity of Illness Index; Treatment Outcome | 2012 |
Comparison of the efficacy between paroxetine and sertraline augmented with aripiprazole in patients with refractory major depressive disorder.
Topics: Adult; Aged; Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Depressive Disorder, Treatment-Resistant; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Paroxetine; Piperazines; Psychiatric Status Rating Scales; Quinolones; Sertraline | 2012 |
3 other study(ies) available for sertraline and Depressive Disorder, Treatment-Resistant
| Article | Year |
|---|---|
Dysfunction of Serotonergic and Dopaminergic Neuronal Systems in the Antidepressant-Resistant Impairment of Social Behaviors Induced by Social Defeat Stress Exposure as Juveniles.
Topics: Animals; Antidepressive Agents; Aripiprazole; Brain; Depressive Disorder, Treatment-Resistant; Desipramine; Disease Models, Animal; Dominance-Subordination; Dopamine; Drug Therapy, Combination; Male; Mice, Inbred C57BL; Mice, Inbred ICR; Norepinephrine; Serotonin; Sertraline; Sexual Maturation; Social Behavior; Stress, Psychological | 2018 |
Stem cell therapy: a new approach to the treatment of refractory depression.
Topics: Animals; Antidepressive Agents; Brain; Combined Modality Therapy; Depressive Disorder, Treatment-Resistant; Disease Models, Animal; Disks Large Homolog 4 Protein; GABAergic Neurons; Intracellular Signaling Peptides and Proteins; Membrane Proteins; Neural Stem Cells; Parvalbumins; Rats, Wistar; Sertraline; Stem Cell Transplantation | 2014 |
Why is mechanism of action important in antidepressant treatment?
Topics: Adult; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Dose-Response Relationship, Drug; Drug Substitution; Female; Follow-Up Studies; Humans; Sertraline; Surveys and Questionnaires | 2016 |